Excelsior Medical Co., Ltd. (TPE:4104)
70.70
-1.30 (-1.81%)
Jul 17, 2026, 1:30 PM CST
Excelsior Medical Revenue
Excelsior Medical had revenue of 2.34B TWD in the quarter ending March 31, 2026, with 9.01% growth. This brings the company's revenue in the last twelve months to 8.98B, up 3.90% year-over-year. In the year 2025, Excelsior Medical had annual revenue of 8.79B with 2.94% growth.
Revenue (ttm)
8.98B
Revenue Growth
+3.90%
P/S Ratio
1.51
Revenue / Employee
65.09M
Employees
138
Market Cap
13.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.79B | 250.69M | 2.94% |
| Dec 31, 2024 | 8.54B | 305.14M | 3.71% |
| Dec 31, 2023 | 8.23B | 1.05B | 14.56% |
| Dec 31, 2022 | 7.19B | 613.68M | 9.34% |
| Dec 31, 2021 | 6.57B | -102.34M | -1.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 17.50B |
| Grape King Bio | 10.28B |
| YungShin Global Holding | 8.04B |
| Handa Pharmaceuticals | 1.76B |
| EirGenix | 1.13B |
| TCM Biotech International | 703.09M |
| Foresee Pharmaceuticals | 401.12M |
| Gongwin Biopharm Holdings | 38.28M |